Latest stories on AARD
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
PR Newswire33 · bearishgeneral
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
PR Newswire33 · bearishgeneral
Aardvark Therapeutics: Regulatory Uncertainty Clouds ARD-101 Path Forward
Seeking Alpha33 · bearishgeneral
Aardvark plummets on FDA clinical hold on Prader-Willi Syndrome asset
Seeking Alpha22 · bearishproduct/pr